Last reviewed · How we verify

HRV Lyophilized

GlaxoSmithKline · Phase 3 active Biologic

HRV Lyophilized is a live attenuated human rotavirus vaccine that stimulates immune responses against rotavirus infection.

HRV Lyophilized is a live attenuated human rotavirus vaccine that stimulates immune responses against rotavirus infection. Used for Prevention of rotavirus gastroenteritis in infants and young children.

At a glance

Generic nameHRV Lyophilized
SponsorGlaxoSmithKline
Drug classLive attenuated vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains a weakened form of human rotavirus that replicates in the intestinal tract, triggering both humoral and mucosal immune responses. This primes the immune system to recognize and neutralize wild-type rotavirus upon natural exposure, preventing severe gastroenteritis in infants and young children.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: